Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Significant Increase in Short Interest
by Doug Wharley · The Cerbat GemJaguar Animal Health, Inc. (NASDAQ:JAGX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 599,897 shares, a growth of 24.7% from the March 31st total of 481,255 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 686,294 shares, the short-interest ratio is currently 0.9 days.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Jaguar Animal Health presently has an average rating of “Hold” and an average target price of $2,100.00.
View Our Latest Research Report on JAGX
Jaguar Animal Health Trading Down 3.9%
Shares of NASDAQ JAGX traded down $0.27 during midday trading on Friday, reaching $6.69. The company had a trading volume of 61,906 shares, compared to its average volume of 19,537. Jaguar Animal Health has a one year low of $6.63 and a one year high of $462.00. The company has a quick ratio of 0.29, a current ratio of 0.50 and a debt-to-equity ratio of 4.08. The firm’s fifty day moving average price is $16.45 and its 200-day moving average price is $34.15. The stock has a market cap of $2.48 million, a PE ratio of -0.20 and a beta of 0.02.
About Jaguar Animal Health
Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.
Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.